Hyperlipidemia and Hypertension combination drug moves to triple-therapy from dual-therapy

Hypertension + hyperlipidemia combination drug market is gradually shifting its focus to the triple-drug combinations.

According to the UBIST, the market for hypertension + hyperlipidemia combination drugs reached about KRW 33 billion last year, more than doubled from 2019.

AmosartanQ (Hanmi Pharmaceutical), the largest product, has expanded its prescription to KRW 9.5 billion and made it to KRW 10 billion mark, and Dukaro (Boryung Pharmaceutical), which newly joined the market, entered the leading competition with a prescription amount of KRW 6.4 billion in its first year.

Ollomax (Daewoong Pharmaceutical Co.) was also close to the KRW 5 billion mark, followed by Telostop Plus (Ildong Pharmaceutical) with KRW 3.2 billion and Duowell A (Yuhan Corp.) with KRW 2 billion.

In addition, Treble (Celltrion Pharm), Telmiduo Plus (Jeil Pharmaceutical Co.), and Tri-in-one (Daewon Pharmaceutical Co.) exceeded KRW 1.5 billion, while Ex-one R (HK inno.N) also rose to KRW 1 billion mark.

As the triple-drug combinations expanded their sales, that of dual-therapies decreased. Last year, the market size maintained at KRW 120 billion, but it was reduced by 3.7% from 2019.

Particularly, the prescription amount of all large products fell at once. Caduet (Pfizer), which pioneered hypertension + hyperlipidemia combination drug market, was the only one to sustain the KRW 20 billion mark of prescription, but it shrunk by 15% compared to 2019.

Duowell (Yuhan Corp.) and Rovelito (Hanmi Pharmaceutical Co.), which recorded KRW 20 billion along with Caduet, also dropped to KRW 18.5 billion.

Olostar (Daewoong Pharmaceutical Co.)’s prescription decreased from KRW 12.5 billion to KRW 10.9 billion, while Livaro V (JW Pharmaceutical Corp.) was pushed back to KRW 8.2 billion, a little further away from the KRW 10 billion mark.

On the other hand, Rosuampin (Yuhan Corp.)’ increased from KRW 5.1 billion to KRW 6.8 billion, marking the only growth among the dual-therapy drugs that recorded more than KRW 5billion prescription last year.

The prescriptions for Rovatitan (LG Chem) and Telestop (Ildong Pharmaceutical) decreased slightly from 2019 but maintained KRW 5 billion mark.